Jason H Karlawish MD

Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania Perelman School of Medicine Director of the Penn Neurodegenerative Disease Ethics and Policy Program Associate Director of the Clinical Core and Co-Associate Director of the Alzheimer’s Disease Core Center Co-Director of the Penn Memory Center Director of Alzheimer’s Disease Core

Join to view full profile

3615 Chestnut StRalston Penn CenterPhiladelphia, PA 19104
Phone+1 215-662-2746

Dr. Karlawish is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karlawish's full profile Already have an account?

Education & Training

University of ChicagoFellowship, Geriatric Medicine (Internal Medicine), 1995 - 1997
Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 1991 - 1994
Northwestern University The Feinberg School of MedicineClass of 1991

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

PA State Medical License 1997 - 2026
IL State Medical License 1994 - 1999
MD State Medical License 1993 - 1994
American Board of Internal Medicine Geriatric Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

Memory Aid for Informed Consent in Alzheimer's Research
COMPLETED
NA
Encouraging Walking in Older Adults
COMPLETED
NA
Social Goals and Individual Incentives to Promote Walking in Older Adults
COMPLETED
NA

Publications & Presentations

PubMed

1 citations
Learning about a heightened genetic risk for dementia: Expected stigma is greater than experienced stigma.
Shana D Stites, Mehek Dedhia, Kristin Harkins, Jason Karlawish, Jessica B Langbaum
Psychology and Aging. 2026-08-01
CONNECT4 APOE: A randomized trial of telephone versus real-time two-way videoconference for disclosure of APOE genotype results in cognitively unimpaired adults.
Elisabeth McCarty Wood, Jessica B Langbaum, Brian L Egleston, Demetrios Ofidis, Cara Cacioppo
Alzheimer's & Dementia. 2026-07-01
Designing Consent Processes for Research With Older Adults Who May Lack Decisional Capacity: A Guide for Investigators.
Emily A Largent, Stephanie R Morain, Jason Karlawish
Journal of the American Geriatrics Society. 2026-06-01

Journal Articles

Desktop Medicine and the Practice of Wealth Care
Jason Karlawish, MD, JAMA Internal Medicine
Short-Term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment
Jeffrey M Burns, Keith A Johnson, Reisa A Sperling, Jason Karlawish, JAMA Neurology
Study Partners Should Be Required in Preclinical Alzheimer’s Disease Trials
Joshua D Grill, Jason Karlawish, BioMed Central

Authored Content

The FDA Needs a Risk Evaluation and Mitigation Strategy for Alzheimer’s Drug LecanemabJune 2023
How Can the Latest Alzheimer’s Therapy Reach Patients? Follow This Trustworthy ProcessOctober 2022
We Can’t Drug Our Way Out of Despair over Alzheimer’s | OpinionAugust 2021

Press Mentions

Analysis of Alzheimer’s Drugs Stirs Debate About Their EffectivenessApril 16th, 2026
An Expensive Alzheimer’s Lifestyle Plan Offers False Hope, Experts SayMay 21st, 2025
Julie Jason: Dementia Is Not a Solo Affair. Be Financially PreparedMay 17th, 2025

Grant Support

Penn Artificial Intelligence and Technology Collaboratory for Healthy AgingUNIVERSITY OF PENNSYLVANIA2021–2026
Parkinsons Disease And Research Consent CapacityNational Institute Of Neurological Disorders And Stroke2009–2011
Core--Education And Information TransferNational Institute On Aging2006–2010
Consent Methods And Participation In Geriatric Clinical ResearchNational Institute Of Mental Health2007–2009
Understanding Attitudes About Research Advance PlanningNational Institute Of Mental Health2006